+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acute Myeloid Leukemia Therapeutics Market - Global Forecast 2026-2032- Product Image
Acute Myeloid Leukemia Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Acute Myeloid Leukemia Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 198 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5665822
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Acute Myeloid Leukemia Therapeutics Market is transforming as clinical innovation, regulatory shifts, and commercial imperatives converge, demanding new approaches for effective therapy development and market access. Senior decision-makers must stay attuned to hidden operational risks, evolving care standards, and pathway opportunities shaping this global sector.

Market Snapshot: Acute Myeloid Leukemia Therapeutics Market

The Acute Myeloid Leukemia Therapeutics Market grew from USD 1.12 billion in 2025 to USD 1.25 billion in 2026. It is expected to continue expanding at a CAGR of 12.74%, reaching USD 2.61 billion by 2032. This growth is supported by advances in targeted therapies, sophisticated diagnostics, and a complex ecosystem of stakeholders navigating clinical, regulatory, and commercial drivers.

Scope & Segmentation

  • Therapy Format: Biologic agents, cell therapies, gene therapies, and small molecules underpin emerging and established treatment paradigms.
  • Mechanism of Action: BCL-2 inhibitors, DNA methyltransferase inhibitors, HDAC inhibitors, immunomodulatory agents, and tyrosine kinase inhibitors address distinct leukemic pathways.
  • Clinical Setting: First-line, second-line, and third-line-plus therapies require differentiated trial designs and patient selection strategies.
  • Administration Route: Intravenous, oral, and subcutaneous delivery platforms impact adherence, monitoring, and distribution frameworks.
  • Patient Demographics: Adult, geriatric, and pediatric populations demand customized safety evaluations and dosing adjustments.
  • End User Type: Hospital pharmacies, retail environments, and specialty clinics each shape commercial deployment and training needs.
  • Regional Focus: Americas, Europe/Middle East/Africa, and Asia-Pacific regions present diverse regulatory, reimbursement, and access profiles.
  • Technology Integration: Precision diagnostics, comprehensive genomic profiling, and digital health tools increasingly drive biomarker-based development and real-world implementation.

Primary Keyword: Acute Myeloid Leukemia Therapeutics Market

Key Takeaways

  • Clinical innovation is shifting rapidly, with precision medicine tools enabling finer patient stratification and adaptive treatment algorithms.
  • Emerging cell and gene therapies, along with engineered biologic formats, are expanding options for disease modulation and offering new routes to remission.
  • Payer scrutiny demands robust demonstration of long-term benefit, cost-effectiveness, and real-world effectiveness, prompting early alignment of evidence plans.
  • Cross-sector collaboration among biotech firms, academic groups, contract manufacturers, and diagnostic providers is essential to accelerate development and manage operational complexity.
  • Therapeutic segmentation by mechanism, format, and administration route supports more precise portfolio prioritization and commercialization strategies.
  • Regional variability in clinical infrastructure, diagnostics, and reimbursement shapes trial execution, regulatory navigation, and adoption roadmaps for new agents.

Tariff Impact and Supply Chain Considerations

Recent US tariff changes impose new complexities on sourcing, manufacturing, and procurement for AML therapeutics. The resulting cost pressures have prompted shifts toward regional manufacturing hubs, longer-term supplier agreements, and greater focus on supply chain transparency. Organizations are optimizing operational resilience through nearshoring, stockpiling, and multi-source strategies, integrating tariff risks into broader planning for uninterrupted clinical and commercial supply.

Methodology & Data Sources

This research synthesizes peer-reviewed clinical literature, regulatory guidance documents, trial registry data, and primary interviews with key opinion leaders in hematology and health economics. Insights were cross-validated for alignment with contemporary treatment standards, emerging payer requirements, and evolving global market dynamics to ensure a balanced, evidence-backed perspective.

Why This Report Matters

  • Enables evidence-based decision-making for investment prioritization, development program design, and commercial alignment in the context of AML.
  • Delivers actionable insight on clinical, regulatory, and payer trends shaping the future of AML therapy innovation and adoption globally.
  • Offers a framework for navigating operational challenges, risk management, and strategic collaborations critical for successful market entry and growth.

Conclusion

The AML therapeutics industry is at a pivotal point, requiring integrated approaches that bridge clinical advances and operational resilience. Aligning with payer and regulatory expectations while strengthening partnerships across diagnostics and manufacturing supports both patient access and sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Acute Myeloid Leukemia Therapeutics Market, by Therapy Type
8.1. Biologic
8.1.1. Antibody Drug Conjugates
8.1.2. Fusion Proteins
8.1.3. Monoclonal Antibodies
8.2. Cell Therapy
8.2.1. CAR T Cell Therapy
8.2.2. Stem Cell Transplantation
8.3. Gene Therapy
8.4. Small Molecule
9. Acute Myeloid Leukemia Therapeutics Market, by Mechanism Of Action
9.1. BCL-2 Inhibitors
9.2. DNA Methyltransferase Inhibitors
9.3. HDAC Inhibitors
9.4. Immunomodulatory Agents
9.5. Tyrosine Kinase Inhibitors
10. Acute Myeloid Leukemia Therapeutics Market, by Line Of Therapy
10.1. First Line
10.2. Second Line
10.3. Third Line And Beyond
11. Acute Myeloid Leukemia Therapeutics Market, by Route Of Administration
11.1. Intravenous
11.2. Oral
11.3. Subcutaneous
12. Acute Myeloid Leukemia Therapeutics Market, by Patient Age
12.1. Adult
12.2. Geriatric
12.3. Pediatric
13. Acute Myeloid Leukemia Therapeutics Market, by End User
13.1. Hospital Pharmacy
13.2. Retail Pharmacy
13.3. Specialty Clinic
14. Acute Myeloid Leukemia Therapeutics Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Acute Myeloid Leukemia Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Acute Myeloid Leukemia Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Acute Myeloid Leukemia Therapeutics Market
18. China Acute Myeloid Leukemia Therapeutics Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Actinium Pharmaceuticals, Inc.
19.7. Agios Pharmaceuticals, Inc.
19.8. Amgen Inc.
19.9. Astellas Pharma Inc.
19.10. Astex Pharmaceuticals, Inc. by Otsuka Group
19.11. Celgene Corporation
19.12. CTI BioPharma Corp.
19.13. Cyclacel Pharmaceuticals, Inc.
19.14. Daiichi Sankyo Company, Limited
19.15. Eisai Co., Ltd.
19.16. F. Hoffmann-La Roche AG
19.17. GlaxoSmithKline plc
19.18. Janssen Global Services, LLC
19.19. Jazz Pharmaceuticals PLC
19.20. Johnson & Johnson Services, Inc.
19.21. MEI Pharma, Inc.
19.22. Merck & Co., Inc.
19.23. Merus N.V.
19.24. Novartis AG
19.25. Pfizer Inc.
19.26. Sanofi S.A.
19.27. Sun Pharmaceutical Industries Ltd.
19.28. Takeda Pharmaceutical Company Limited
19.29. Teva Pharmaceutical Industries Ltd.
19.30. The Bristol Myers Squibb Company
List of Figures
FIGURE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 128. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 129. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 130. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 131. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 133. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 145. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 146. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 147. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 148. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 149. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 151. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 164. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 165. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 167. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 168. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 170. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 173. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 174. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 175. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 176. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 177. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 179. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 191. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 192. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 193. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 194. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 195. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 197. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 200. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 201. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 202. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 203. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 204. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 206. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 209. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 210. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 211. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 212. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 213. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 215. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 228. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 229. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 230. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 231. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 232. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 234. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Acute Myeloid Leukemia Therapeutics market report include:
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc. by Otsuka Group
  • Celgene Corporation
  • CTI BioPharma Corp.
  • Cyclacel Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Merus N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company

Table Information

Report AttributeDetails
No. of Pages198
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.25 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.61 Billion
Compound Annual Growth Rate12.7%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report - Product Image

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report

  • Report
  • 356 Pages
  • Global
From
Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2025-2033 - Product Image

Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2025-2033

  • Report
  • 144 Pages
  • Global
From
2025 Global Forecast for Acute Myeloid Leukemia Treatment Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Acute Myeloid Leukemia Treatment Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Leukemia Therapeutics Market - Global Forecast 2026-2032 - Product Image

Leukemia Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Relapsed/refractory Acute Myeloid Leukemia (AML)- Pipeline Insight, 2025 - Product Image

Relapsed/refractory Acute Myeloid Leukemia (AML)- Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From

About the Acute Myeloid Leukemia Drug Market

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is the most common type of acute leukemia in adults. Treatment for AML typically involves chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat AML include cytarabine, daunorubicin, and idarubicin. These drugs are used to kill cancer cells, reduce the size of tumors, and reduce the risk of relapse. Other drugs used to treat AML include decitabine, gemtuzumab ozogamicin, and venetoclax. These drugs are used to target specific genetic mutations that are associated with AML. The AML drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Novartis, Pfizer, Celgene, Bristol-Myers Squibb, and Merck. Other companies in the market include AbbVie, AstraZeneca, Johnson & Johnson, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.